[go: up one dir, main page]

MX2018010291A - Vacunas novedosas contra el virus de zika. - Google Patents

Vacunas novedosas contra el virus de zika.

Info

Publication number
MX2018010291A
MX2018010291A MX2018010291A MX2018010291A MX2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A
Authority
MX
Mexico
Prior art keywords
mammal
zika
zika virus
immune response
plasmid dna
Prior art date
Application number
MX2018010291A
Other languages
English (en)
Inventor
Muthumani Karuppiah
Weiner David
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018010291A publication Critical patent/MX2018010291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un aspecto de la presente invención se refiere a construcciones de ácido nucleico capaces de expresar un antígeno de Zika que provoca una respuesta inmunitaria en un mamífero contra el virus de Zika, y métodos de usos de estas. Además, hay vacunas de plásmidos de ADN capaces de generar una respuesta inmunitaria contra un virus de Zika en un mamífero, que comprenden un plásmido de ADN y un excipiente farmacéuticamente aceptable y métodos de uso de estas. El plásmido de ADN es capaz de expresar un antígeno de Zika en una célula del mamífero en una cantidad efectiva para provocar una respuesta inmunitaria en el mamífero que tenga reactividad cruzada frente a todas las cepas de Zika.
MX2018010291A 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika. MX2018010291A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US201762462249P 2017-02-22 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus

Publications (1)

Publication Number Publication Date
MX2018010291A true MX2018010291A (es) 2019-06-06

Family

ID=59685658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010291A MX2018010291A (es) 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika.
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Country Status (10)

Country Link
US (2) US11648303B2 (es)
EP (1) EP3419660A4 (es)
JP (3) JP7012365B2 (es)
KR (1) KR20190003471A (es)
CN (2) CN115927399A (es)
AU (3) AU2017222644B2 (es)
BR (1) BR112018017307A2 (es)
CA (1) CA3015792A1 (es)
MX (2) MX2018010291A (es)
WO (1) WO2017147458A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MX2018010291A (es) 2016-02-25 2019-06-06 Univ Pennsylvania Vacunas novedosas contra el virus de zika.
WO2018071405A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
MX2020004542A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Metodo para inactivar el virus del zika y para determinar la inactivacion total.
EP3717638A4 (en) 2017-11-30 2022-03-09 Takeda Vaccines, Inc. PROCEDURES FOR INACTIVATING ZIKA VIRUS AND RELATED PROCEDURES
WO2019113285A2 (en) * 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
EP3826672A4 (en) * 2018-07-23 2022-04-20 The University of Adelaide VACCINE AGAINST THE ZIKA VIRUS
US20220017605A1 (en) * 2018-10-31 2022-01-20 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
KR102553857B1 (ko) * 2021-02-05 2023-07-17 에스티팜 주식회사 신규 핵산 분자

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471983T1 (de) * 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
ES2685435T3 (es) 2008-01-11 2018-10-09 Inovio Pharmaceuticals, Inc. Nuevas vacunas frente a múltiples subtipos del virus del dengue
CA2740598C (en) 2008-11-17 2018-05-22 Mathura P. Ramanathan Antigens that elicit immune response against flavivirus and methods of using same
WO2011032179A1 (en) * 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
CN102712931A (zh) 2009-11-02 2012-10-03 宾夕法尼亚大学托管会 口蹄疫病毒病毒(fmdv)共有蛋白质、其编码序列及由其制备的疫苗
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
WO2011119716A2 (en) * 2010-03-24 2011-09-29 Research Development Foundation Flavivirus host range mutations and uses thereof
EP2649178B8 (en) * 2010-12-09 2017-08-30 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
EP2670443A4 (en) 2011-01-31 2015-10-14 Univ Pennsylvania FOR NUCLEIC ACID MOLECULAR ENCODING NEW HERPES ANTIGENES, VACCINES THEREOF AND METHOD OF USE THEREOF
DK2788478T3 (en) * 2011-12-09 2017-10-09 Pasteur Institut Multiplex IMMUNSCREENINGSASSAY
AU2014228497B2 (en) * 2013-03-15 2017-03-02 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
CA2992531C (en) * 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
MA42502A (fr) * 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MX2018009917A (es) * 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
MX2018010291A (es) * 2016-02-25 2019-06-06 Univ Pennsylvania Vacunas novedosas contra el virus de zika.
WO2018014113A1 (en) * 2016-07-18 2018-01-25 Variation Biotechnologies Inc. Vaccine compositions for treatment of zika virus
MX2019003156A (es) * 2016-09-19 2019-08-29 Univ Pennsylvania Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
AU2018207408B2 (en) * 2017-01-11 2025-02-27 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against Zika virus
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Also Published As

Publication number Publication date
KR20190003471A (ko) 2019-01-09
WO2017147458A1 (en) 2017-08-31
JP7012365B2 (ja) 2022-03-04
CA3015792A1 (en) 2017-08-31
CN109152826B (zh) 2022-11-04
US12419945B2 (en) 2025-09-23
US20240115689A1 (en) 2024-04-11
AU2021258056B2 (en) 2024-04-04
JP2024096281A (ja) 2024-07-12
BR112018017307A2 (pt) 2019-01-08
JP2022023241A (ja) 2022-02-07
MX2023006203A (es) 2023-06-12
JP7555325B2 (ja) 2024-09-24
US20210315987A1 (en) 2021-10-14
CN115927399A (zh) 2023-04-07
EP3419660A4 (en) 2019-11-06
CN109152826A (zh) 2019-01-04
US11648303B2 (en) 2023-05-16
AU2024204641A1 (en) 2024-07-25
JP2019506175A (ja) 2019-03-07
AU2017222644A1 (en) 2018-09-13
EP3419660A1 (en) 2019-01-02
AU2017222644B2 (en) 2021-07-29
AU2021258056A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2018010291A (es) Vacunas novedosas contra el virus de zika.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
Liu Immunologic basis of vaccine vectors
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
CO2018005258A2 (es) Vacuna del virus herpes simple
CL2017000987A1 (es) Partículas tipo virus modificadas de cmv
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2023012264A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
AR110632A1 (es) Vectores del adenovirus canino
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
CO2017007105A2 (es) Nuevos virus de tilapia
EA201891460A1 (ru) Композиция дендритных клеток
EA201992282A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
RU2016116988A (ru) Вакцина против haemophilus parasuis серологического типа 4
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
BR112014014390A2 (pt) levedura recombinante, seus usos, processo para vacinação, oligonucleotídeo, vetor de expressão, e método de produção de uma composição de vacina
MX2015011485A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él